Current share price for IVX : $0.044 0.001 (2.22%)+
Invion Limited (IVX), an ASX-listed company, is life-science company that is guiding the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases.
| ASX Code | IVX |
| Website | http://www.inviongroup.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 4 |
| IVX Share Price | $0.044 |
| Day High | $0.044 |
| Day Low | $0.044 |
| Last Close | $0.045 |
| IVX Share Price Movement | $0.00 ( 2.22% ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Invion Limited (IVX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$8.81 | -$12.20 | 39.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$5.63 | -$8.80 | 247.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$1.61 | -$2.50 | -31.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $802M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Invion Limited (IVX) | $4M | 0.3950 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,691M | -0.7857 | 0.0743 | 1.2000 | 57.5419 | 53.5600 | 24.3455 | 0.00% | 0.00% | 0.00% |
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 0.46 | 0.00 |
| Market | 0.29 | 13.20 | 1.18 | 0.70 |
| Sector | 0.39 | 27.30 | 2.56 | 2.17 |
| Name | Position | Start Date |
|---|---|---|
| Mr Chiat Thian Chew | Chief Executive Officer, Executive Chairman, Executive Director | 1 Dec 2017 |
| Mr Alan Yamashita | Non-Executive Director | 12 Feb 2019 |
| Mr Alistair Bennallack | Non-Executive Director | 22 Oct 2020 |
| Ms Melanie Jaye Leydin | Non-executive director, Company Secretary | 31 Aug 2024 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 23 Jul 2025 | CHEW, Chiat | Issued | Options | 10,000,000 | $0.015 | $150,000.000 |
| 18 Jul 2025 | BENNALLACK, Alistair | Issued | Options | 181,064 | $0.015 | $2,715.960 |
| 18 Jul 2025 | YAMASHITA, Alan | Issued | Options | 115,541 | $0.015 | $1,733.115 |
See all changes in directors' interest & trades for Invion Limited (IVX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Invion Limited (IVX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 11,457,215 (13.38%) | Honsue Cho |
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 26 August 2026 | Report (Annual) |
| 26 August 2026 | Report (Prelim) |
| 16 June 2026 | Issued Shares |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.